| Price | $2.47 |
| Year Range | $2.45 – $5 |
| Market Cap | $152M |
| PE Ratio | 6.02 |
| Industry | Biotechnology |
What Is Voyager Therapeutics’s AI Stock Analysis?
Voyager Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Voyager Therapeutics’s momentum in near-real time.
Voyager Therapeutics (VYGR) has an AltIndex AI Score of 40/100, currently a Sell signal. The AI Score distills Voyager Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Voyager Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Voyager Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving VYGR’s AI Score?
Fundamentals
Revenue for the last quarter was $3.2M. This is an increase of 22.06% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 39.13%, which may be a cause for concern. Net income for the last quarter was $-24M. This is an increase of -12.40% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -26.69%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-23M. This is an increase of -16.22% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -30.00%, suggesting positive year-over-year growth. The current P/E ratio is 6.02. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Voyager Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $2.47. This represents a decrease of 27.35% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 52.04%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $2.54, which is lower than the previous SMA10 of $2.57. This suggests a potential downward trend in price movement. The RSI is 32.6, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Voyager Therapeutics is low (an estimate of only 42% of employees have a positive outlook), a concerning sign. Add to that that the business outlook is down by -11% in the last couple of months, an even more concerning trend. Voyager Therapeutics has an estimate of 5,000 visitors to their webpage. The number of visitors is down by -17% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Voyager Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Voyager Therapeutics has 920 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Voyager Therapeutics’s market sentiment.
Frequently Asked Questions: Voyager Therapeutics AI Stock Analysis
Voyager Therapeutics's AltIndex AI Score is 40/100, currently a Sell signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Voyager Therapeutics a Sell (40/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Voyager Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the VYGR AI Score or sign up to read the full thesis.
